# Israel Innovation Authority

> Israel Innovation Authority is a VC fund backing Health Care. See 206 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Jerusalem, Israel
- Total investments: 206
- Last investment: Jun 2026
- Lead investor: 47%
- Last fund: Jul 2023
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/5094726
- X (Twitter): https://twitter.com/innovationaut
- Website: https://innovationisrael.org.il
- Facebook: https://www.facebook.com/InnovationAuthority

Israel Innovation Authority is a VC fund in Jerusalem focused on Health Care and Artificial Intelligence. The Israel Innovation Agency, the Innovation Authority, was established in 1965 as the Office of the Chief Scientist of the Ministry of Industry and Trade and was designed as a body that supports R & D conducted in the framework of government research institutes. Industrial development in order to increase industrial exports of high-techproducts. The Chief Scientist focused on reducing the risk by participating in financing the project, which the private companies chose and led.

## Contacts

5 contacts available for Israel Innovation Authority. Shizune tracks 5 team members at Israel Innovation Authority. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/israel-innovation-authority?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $500k–$5M |
| Grant | $130k–$3.5M |
| Pre-Seed | $150k–$2.1M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 49 | 24% |
| Artificial Intelligence | 37 | 18% |
| Biotechnology | 35 | 17% |
| Medical Device | 29 | 14% |
| Software | 27 | 13% |

177 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Grant | 100 | 49% |
| Seed | 42 | 20% |
| Pre-Seed | 24 | 12% |
| Series A | 8 | 4% |
| Funding Round | 6 | 3% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 146 | 71% |
| United States | 15 | 7% |
| Mali | 1 | 0% |
| Canada | 1 | 0% |
| United Kingdom | 1 | 0% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Aviv Zeevi Balasiano | Head Of Sector | 0 | https://shizune.co/investors/profile/aviv-zeevi-balasiano |
| Dror Bin | Chief Executive Officer | 1 | https://shizune.co/investors/profile/dror-bin |
| Itai Kela | Senior Director, Head of Healthcare & Biotechnology | 0 | https://shizune.co/investors/profile/itai-kela |
| Pinchas Gilboa | Technological Evaluator | 0 | https://shizune.co/investors/profile/pinchas-gilboa |
| Tomer Gal | Professional Evaluator for the Israel Innovation Authority | 0 | https://shizune.co/investors/profile/tomer-gal-2fd9 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Brevel | Brevel developed a disruptive cultivation technology for sustainable, low cost and high quality production of microalgae for various yet untapped markets. The technology is based on high-tech indoor, sterile and fully automated systems which are illuminated from within at high intensity. The technology enables the surprising results of more than90% cost reduction and up to 200 higher yields compared to current alternatives. Brevel is using the advantageous production capabilities to enter multiple markets where microalgae derived products are needed. | $1M | Grant | Jun 23, 2026 |  |
| NanoGhosts | NanoGhosts’ technology is based on its founder’s research, that the Technion's commercial unit has patented in the U.S. and Europe. |  | Grant | Jun 22, 2026 |  |
| Inspira Technologies | Inspira Technologies is an innovative Medical Technology Company focused on the acute respiratory care market. The ART, Inspira’s novel technology, can address the unmet need of providing acute respiratory treatment that prevents mechanical ventilation while patients are awake and breathing spontaneously. | $1M | Grant | Jun 09, 2026 |  |
| Q-Factor | Q‑Factor is building the physical infrastructure needed to scale quantum computing. They design neutral‑atom quantum systems from the ground up to support millions of qubits.They target the key bottlenecks of control, connectivity, and error correction between today’s prototypes and commercially viable quantum machines. |  | Grant | Apr 06, 2026 |  |
| Scala Biodesign | Scala Biodesign offers partners a one-of-a-kind computational solution to drastically boost the value of proteins and accelerate their development into commercial products. | $16M | Series A | Mar 31, 2026 |  |
| Sub-Q Bionics | Sub-Q Bionics is a medtech company, that aids the management of chronic pain and debilitating symptoms of lymphedema specially for women. | $1.5M | Pre-Seed | Mar 31, 2026 |  |
| Scala Biodesign | Scala Biodesign offers partners a one-of-a-kind computational solution to drastically boost the value of proteins and accelerate their development into commercial products. | $4.7M | Grant | Mar 31, 2026 |  |
| Kailo Pharma | Kailo Pharma is an Israel-based biotech startup focused on developing innovative drug treatments for post-traumatic stress disorder (PTSD). | $2.1M | Pre-Seed | Mar 22, 2026 |  |
| AgriPass | AgriPass offers a robotic weeding solution for conventional agriculture. | $1.7M | Grant | Mar 05, 2026 |  |
| MeMed | MeMed Diagnostics is a personalized diagnostics company founded in 2009. They are here to improve patient care, empower physicians, and lower health-care costs through rapid and actionable diagnostics for infectious diseases. Their main focus is preventing antibiotics misuse.Antibiotics are the most prescribed class of drugs worldwide with aglobal market of 25-30 billion $US. Up to 70% of antibiotics are estimated to be prescribed inappropriately, making them the most misused drug class in the world. Antibiotics misuse leads to ineffective treatment, emergence of resistant strains of bacteria, and is estimated to cost healthcare systems worldwide tens of billions of dollars annually. Their platform, the ImmunoDx™, leverages the world’s most accurate diagnostic system for differentiating bacteria from viruses, crafted by nature, the body’s immune system.ImmunoDx™ combines proprietary biomarkers, algorithms, and clinical know-how to identify the source of infection (virus vs bacteria, bacterial spectrum), by decoding the immune system`s differential response to different pathogens. This unique approach enables ImmunoDx™ to address some of the major challenges facing currently available diagnostics for infectious diseases. | $2M | Grant | Jan 12, 2026 |  |

10 of 206 investments shown.

## Co-investors
- [Trendlines Group](https://shizune.co/investors/profile/trendlines-group) — VC Fund, 8 deals together
- [BIRD Foundation](https://shizune.co/investors/profile/bird-foundation) — VC Fund, 5 deals together
- [Agriline](https://shizune.co/investors/profile/agriline) — VC Fund, 3 deals together
- [eHealth Ventures](https://shizune.co/investors/profile/ehealth-ventures) — VC Fund, 3 deals together
- [Maccabi Fund](https://shizune.co/investors/profile/maccabi-fund) — VC Fund, 3 deals together
- [NGT Healthcare II](https://shizune.co/investors/profile/ngt-healthcare-ii) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SVG Ventures](https://shizune.co/investors/profile/svg-ventures) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Omnivore](https://shizune.co/investors/profile/omnivore-partners) — VC Fund

### Similar stage
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund

### Similar country
- [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund
- [Oqal](https://shizune.co/investors/profile/oqal) — VC Fund
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund

## Featured in investor lists
- [All Investors in Middle East](https://shizune.co/investors/investors-middle-east)
- [All VC Funds in Middle East](https://shizune.co/investors/vc-funds-middle-east)
- [All Investors in Israel](https://shizune.co/investors/investors-israel)
- [All VC Funds in Israel](https://shizune.co/investors/vc-funds-israel)
- [SaaS Investors in Middle East](https://shizune.co/investors/saas-investors-middle-east)
- [SaaS VC Funds in Middle East](https://shizune.co/investors/saas-vc-funds-middle-east)

## FAQ

### What does Israel Innovation Authority invest in?

Israel Innovation Authority invests primarily in Health Care, Artificial Intelligence and Biotechnology startups, most often at Grant and Seed stage. Most of the 206 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Israel Innovation Authority's check size?

Israel Innovation Authority typically joins rounds of $500k–$5M at Seed, $130k–$3.5M at Grant and $150k–$2.1M at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Israel Innovation Authority participates in.

### How do I contact Israel Innovation Authority?

Public channels for Israel Innovation Authority include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Israel Innovation Authority?

The team at Israel Innovation Authority includes Aviv Zeevi Balasiano (Head Of Sector), Dror Bin (Chief Executive Officer) and Itai Kela (Senior Director, Head of Healthcare & Biotechnology). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co